These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28640458)

  • 21. The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients.
    An GH; Yun J; Hong YA; Khvan M; Chung BH; Choi BS; Park CW; Choi YJ; Kim YS; Yang CW
    J Immunol Res; 2014; 2014():828732. PubMed ID: 24741626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy Modalities for Antibody Mediated Rejection in Renal Transplant Patients.
    Yilmaz VT; Suleymanlar G; Koksoy S; Ulger BV; Ozdem S; Akbas H; Akkaya B; Kocak H
    J Invest Surg; 2016 Oct; 29(5):282-8. PubMed ID: 27002854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Bortezomib as an Adjunctive Therapy for Refractory Chronic Active Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience.
    Larpparisuth N; Skulratanasak P; Premasathian N; Vongwiwatana A
    Transplant Proc; 2019 Dec; 51(10):3293-3296. PubMed ID: 31732214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step.
    Lachmann N; Duerr M; Schönemann C; Pruß A; Budde K; Waiser J
    J Immunol Res; 2017; 2017():6872046. PubMed ID: 28255562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial.
    Sautenet B; Blancho G; Büchler M; Morelon E; Toupance O; Barrou B; Ducloux D; Chatelet V; Moulin B; Freguin C; Hazzan M; Lang P; Legendre C; Merville P; Mourad G; Mousson C; Pouteil-Noble C; Purgus R; Rerolle JP; Sayegh J; Westeel PF; Zaoui P; Boivin H; Le Gouge A; Lebranchu Y
    Transplantation; 2016 Feb; 100(2):391-9. PubMed ID: 26555944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subclinical antibody-mediated rejection due to anti-human-leukocyte-antigen-DR53 antibody accompanied by plasma cell-rich acute rejection in a patient with cadaveric kidney transplantation.
    Katsuma A; Yamamoto I; Komatsuzaki Y; Niikura T; Kawabe M; Okabayashi Y; Yamakawa T; Katsumata H; Nakada Y; Kobayashi A; Tanno Y; Miki J; Yamada H; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():31-4. PubMed ID: 26971538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss.
    Kozakowski N; Herkner H; Böhmig GA; Regele H; Kornauth C; Bond G; Kikić Ž
    Kidney Int; 2015 Aug; 88(2):332-40. PubMed ID: 25738252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up.
    Billing H; Rieger S; Süsal C; Waldherr R; Opelz G; Wühl E; Tönshoff B
    Transpl Int; 2012 Nov; 25(11):1165-73. PubMed ID: 22897111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
    Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
    Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of Prolonged Treatment With Intravenous Immunoglobulin Infusions for Acute Antibody-mediated Rejection in Kidney Transplant Recipients.
    Bujnowska A; Michon M; Konopelski P; Hryniewiecka E; Jalbrzykowska A; Perkowska-Ptasinska A; Cieciura T; Zagozdzon R; Paczek L; Ciszek M
    Transplant Proc; 2018; 50(6):1720-1725. PubMed ID: 29961551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
    Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
    Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.
    Gheith O; Al-Otaibi T; Halim MA; Mahmoud T; Nair P; Monem MA; Al-Waheeb S; Hassan R; Nampoory N
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):150-155. PubMed ID: 28260457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case Report: Splenic Irradiation for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Allograft Recipients With
    Zhu L; Guo Z; Sa R; Guo H; Li J; Chen G
    Front Immunol; 2021; 12():661614. PubMed ID: 33936098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of chronic active antibody-mediated rejection in renal transplant recipients - a single center retrospective study.
    Chiu HF; Wen MC; Wu MJ; Chen CH; Yu TM; Chuang YW; Huang ST; Tsai SF; Lo YC; Ho HC; Shu KH
    BMC Nephrol; 2020 Jan; 21(1):6. PubMed ID: 31906890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab.
    Kahwaji J; Najjar R; Kancherla D; Villicana R; Peng A; Jordan S; Vo A; Haas M
    Clin Transplant; 2014 May; 28(5):546-53. PubMed ID: 24579925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection.
    Macklin PS; Morris PJ; Knight SR
    Transplant Rev (Orlando); 2017 Apr; 31(2):87-95. PubMed ID: 28187998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results.
    Mella A; Gallo E; Messina M; Caorsi C; Amoroso A; Gontero P; Verri A; Maletta F; Barreca A; Fop F; Biancone L
    World J Transplant; 2018 Sep; 8(5):178-187. PubMed ID: 30211026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of antibody-mediated rejection with double-filtration plasmapheresis, low dose IVIg plus rituximab after kidney transplantation.
    Naciri Bennani H; Daligault M; Noble J; Bardy B; Motte L; Giovannini D; Emprou C; Fiard G; Imerzoukene F; Bourdin A; Masson D; Janbon B; Malvezzi P; Rostaing L; Jouve T
    J Clin Apher; 2021 Aug; 36(4):584-594. PubMed ID: 33783868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of rituximab therapy for treatment of acute humoral rejection.
    Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan BD
    Clin Transplant; 2009; 23(1):63-73. PubMed ID: 19200217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Desensitization Using Bortezomib and High-dose Immunoglobulin Increases Rate of Deceased Donor Kidney Transplantation.
    Jeong JC; Jambaldorj E; Kwon HY; Kim MG; Im HJ; Jeon HJ; In JW; Han M; Koo TY; Chung J; Song EY; Ahn C; Yang J
    Medicine (Baltimore); 2016 Feb; 95(5):e2635. PubMed ID: 26844479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.